Indivior Settles Suboxone Antitrust End-Payer Class For $30 Million
PHILADELPHIA — Seven end-payer plaintiffs on Aug. 19 asked a Pennsylvania federal court to preliminarily approve a $30 million agreement that would settle a 10-year-old complaint that drugmaker Indivior Inc. engaged...To view the full article, register now.
Already a subscriber? Click here to view full article